Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference
Belite Bio (NASDAQ: BLTE) announced that its executive management team will present at the Deutsche Bank ADR Virtual Investor Conference on November 4, 2025 at 10:30 AM ET. The presentation will be webcast and accessible via the conference site at www.adr.db.com/dbvic. A replay will be available for 90 days after the presentation.
The presentation covers corporate strategy and clinical-stage programs focused on degenerative retinal diseases; investors can access the live webcast and on-demand replay through the conference platform.
Belite Bio (NASDAQ: BLTE) ha annunciato che il suo management esecutivo parteciperà alla Deutsche Bank ADR Virtual Investor Conference il 4 novembre 2025 alle 10:30 AM ET. La presentazione sarà trasmessa in webcast e accessibile tramite il sito della conferenza all'indirizzo www.adr.db.com/dbvic. Una replica sarà disponibile per 90 giorni dopo la presentazione.
La presentazione copre la strategia aziendale e i programmi in fase clinica focalizzati sulle malattie degenerative della retina; gli investitori possono accedere al webcast in diretta e alla replay on-demand attraverso la piattaforma della conferenza.
Belite Bio (NASDAQ: BLTE) anunció que su equipo directivo presentará en la Conferencia Virtual de Inversores ADR de Deutsche Bank el 4 de noviembre de 2025 a las 10:30 AM ET. La presentación se transmitirá en webcast y será accesible a través del sitio de la conferencia en www.adr.db.com/dbvic. Una repetición estará disponible durante 90 días después de la presentación.
La presentación cubre la estrategia corporativa y los programas en fase clínica centrados en enfermedades retinian degenerativas; los inversores pueden acceder al webcast en vivo y a la repetición bajo demanda a través de la plataforma de la conferencia.
Belite Bio (NASDAQ: BLTE) 은 이사·경영진이 Deutsche Bank ADR Virtual Investor Conference에서 2025년 11월 4일 오전 10:30 ET에 발표할 예정이라고 발표했습니다. 발표는 웹캐스트로 진행되며 컨퍼런스 사이트 www.adr.db.com/dbvic를 통해 접속할 수 있습니다. 발표 후 90일간 재방송이 제공됩니다.
발표는 기업 전략과 퇴행성 망막 질환에 초점을 맞춘 임상 단계 프로그램을 다룹니다. 투자자들은 컨퍼런스 플랫폼을 통해 라이브 웹캐스트와 주문형 재생을 모두 이용할 수 있습니다.
Belite Bio (NASDAQ: BLTE) a annoncé que son équipe de direction exécutive présentera à la Conférence virtuelle pour investisseurs ADR de Deutsche Bank le 4 novembre 2025 à 10h30 ET. La présentation sera diffusée en webcast et accessible via le site de la conférence à www.adr.db.com/dbvic. Une rediffusion sera disponible pendant 90 jours après la présentation.
La présentation couvre la stratégie d'entreprise et les programmes en phase clinique axés sur les maladies rétiniennes dégénératives; les investisseurs pourront accéder au webcast en direct et à la rediffusion à la demande via la plateforme de la conférence.
Belite Bio (NASDAQ: BLTE) gab bekannt, dass sein Führungsteam auf der Deutsche Bank ADR Virtual Investor Conference am 4. November 2025 um 10:30 Uhr ET präsentieren wird. Die Präsentation wird gestreamt und über die Konferenzseite unter www.adr.db.com/dbvic zugänglich sein. Eine Wiederholung wird 90 Tage nach der Präsentation zur Verfügung stehen.
Die Präsentation behandelt die Unternehmensstrategie und klinische Programme, die sich auf degenerative Netzhauterkrankungen konzentrieren; Investoren können über die Konferenzplattform den Live-Webcast und die On-Demand-Wiederholung abrufen.
Belite Bio (NASDAQ: BLTE) أعلنت أن فريق الإدارة التنفيذية لديه سيقدم في Deutsche Bank ADR Virtual Investor Conference في 4 نوفمبر 2025 الساعة 10:30 صباحاً بالتوقيت الشرقي. ستُبث العرض عبر الويب ويمكن الوصول إليه عبر موقع المؤتمر على www.adr.db.com/dbvic. ستكون إعادة العرض متاحة لـ 90 يوماً بعد العرض. يغطي العرض استراتيجية الشركة والبرامج في مرحلته السريرية التي تركز على أمراض الشبكية التنكسية؛ يمكن للمستثمرين الوصول إلى البث المباشر عبر الويب وإعادة العرض عند الطلب من خلال منصة المؤتمر.
Belite Bio (NASDAQ: BLTE) 宣布，其执行管理团队将于 2025年11月4日东部时间上午10:30 在 Deutsche Bank ADR Virtual Investor Conference 上进行演示。演示将进行网络直播，可通过会议网站 www.adr.db.com/dbvic 访问。演示结束后 90天 内可回放。
演示内容涵盖公司战略和专注于退行性视网膜疾病的临床阶段项目；投资者可通过会议平台访问在线播放和点播回放。
- None.
- None.
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Belite Bio Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the executive management team will present at the Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference hosted by VirtualInvestorConferences.com, on November 4, 2025. Details of the presentation are as follows:
- 10:30 am ET, corporate presentation
Webcast Link Instructions
A webcast of the presentation will be available on the conference website at www.adr.db.com/dbvic. The replay will be accessible for 90 days following the presentation date.
About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as STGD1 and GA in advanced dry AMD, in addition to specific metabolic diseases. Belite’s lead candidate, Tinlarebant, an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye, is currently being evaluated in a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook or visit us at www.belitebio.com.
Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com
Julie Fallon
belite@argotpartners.com
FAQ
When will Belite Bio (BLTE) present at the Deutsche Bank ADR Virtual Investor Conference?
How can investors watch Belite Bio's (BLTE) November 4, 2025 presentation?
Will there be a replay of Belite Bio's (BLTE) Deutsche Bank ADR conference presentation?
What topics will Belite Bio (BLTE) cover at the November 4, 2025 conference?
Is registration required to view the Belite Bio (BLTE) webcast at the Deutsche Bank ADR conference?
